XAIRXAIRHealthcare · Medical Devices

XAIR Stock Forecast: Beyond Air, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.54

The median 12-month analyst price target for Beyond Air, Inc. is $20. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$2.9M
Ticker Nerd rank
32/ 100
Median analyst target
$20
Analysts covering
2
Revenue$1.8M+0.5% y/y
Operating income−$6.6M
Net income−$8.2M
Free cash flow−$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Beyond Air, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
32/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
80
Growth
64
Revisions
47
Quality
44
Volatility
42
Value
15
Issuance
3
Momentum
3

Accruals (80): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (3): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XAIR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XAIR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$10
Low
$20
Median
$30
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026Lake StreetInitiatesBuy$10
27 Mar 2026D. Boral CapitalMaintainsBuy$10
18 Mar 2026D. Boral CapitalMaintainsBuy—
10 Mar 2026D. Boral CapitalMaintainsBuy—
21 Jan 2026D. Boral CapitalMaintainsBuy—
11 Nov 2025D. Boral CapitalMaintainsBuy—
21 Aug 2025D. Boral CapitalMaintainsBuy—
13 Aug 2025D. Boral CapitalMaintainsBuy—
17 July 2025D. Boral CapitalInitiatesBuy—
16 Aug 2024Roth MKMReinstatesBuy$2.00
7 Aug 2024Piper SandlerMaintainsOverweight—
25 June 2024BTIGDowngradeNeutral—
25 June 2024Piper SandlerMaintainsOverweight—
30 Apr 2024Truist SecuritiesMaintainsBuy—
14 Nov 2023Truist SecuritiesMaintainsBuy—
28 July 2023Piper SandlerInitiatesOverweight—
21 July 2023Truist SecuritiesMaintainsBuy—
23 June 2023OppenheimerMaintainsOutperform—
15 June 2023BTIGInitiatesBuy—
29 June 2022Ladenburg ThalmannMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XAIR.

Market Radar

This page is one stock. Monday covers all of them.

XAIR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

XAIR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.3×

Cheaper than 85% of US stocks

Price / book
0.2×

Cheaper than 95% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
12.7%

Higher than 12% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−357.2%

Higher than 4% of US stocks

Return on assets
−49.0%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beyond Air, Inc. has a market value of $2.9M and an enterprise value of $16.5M.

  • Revenue in the twelve months to 30 June 2026: $7.7M. The latest quarter grew 0.5% year on year.

  • Net income over the same four quarters: −$34.4M, a −447.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$277.40.

  • Free cash flow in the twelve months to 30 June 2026: −$19.6M.

  • Shares outstanding: 743,418.

  • Beyond Air, Inc. employs 54 people — $142K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

XAIR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
XAIRBeyond Air, Inc.$2.9M32
TNONTENON Medical, Inc.$2.4M45
AIDX20/20 Biolabs, Inc.$2.1M20
IVFINVO Fertility, Inc.$2.1M29
BJDXBluejay Diagnostics, Inc.$1.9M17
NUWENuwellis, Inc.$1.8M18
PFSAProfusa, Inc.$1.8M19

Take a look at XAIR’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Beyond Air, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about XAIR

What is the XAIR stock price forecast for 2026-2027?

The median 12-month analyst price target for Beyond Air, Inc. is $20, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XAIR stock a buy right now?

Of the 2 analysts covering Beyond Air, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beyond Air, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XAIR?

As at 21 Nov 2026, Beyond Air, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (80 of 100).

Will XAIR stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $20, and Ticker Nerd's factor model ranks Beyond Air, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XAIR stock forecast for 2030?

No analyst covering Beyond Air, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XAIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

What does Beyond Air, Inc. do?

Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems. The company’s core LungFit platform generates nitric oxide from ambient air and delivers it in a controlled way for respiratory care, with applications centered on neonatal respiratory conditions and other serious lung diseases.

Company

About Beyond Air, Inc.

Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems. The company’s core LungFit platform generates nitric oxide from ambient air and delivers it in a controlled way for respiratory care, with applications centered on neonatal respiratory conditions and other serious lung diseases. Beyond Air also operates development programs aimed at extending its nitric oxide technology across additional respiratory, neurological, and oncology-related uses. Its business is organized around Beyond Air, Beyond Cancer, and NeuroNos, reflecting a broader platform approach that combines device engineering with therapeutic development. Headquartered in Garden City, New York, Beyond Air serves the healthcare market through products and programs designed for hospital-based clinical use and specialized medical treatment settings.

CEO Mr. Robert Scott Goodman · 54 employees · United States · https://www.beyondair.net